Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1CNS 1

Conditions

Neuroblastoma 17Glioblastoma 11Melanoma 5Brain Neoplasms 5Rhabdoid Tumor 4Osteosarcoma 4Lymphoma 4Glioma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Wilms Tumor 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2Neurofibromatosis 1 2Neuroectodermal Tumors, Primitive 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Meningioma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Leukemia, Myelomonocytic, Juvenile 2Hepatoblastoma 2

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × fludarabine × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡